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Abstract
Bladder cancer metastasis is virtually incurable with current platinum-based chemotherapy. We used the novel
COXEN informatic approach for in silico drug discovery and identified NSC-637993 and NSC-645809 (C1311), both
imidazoacridinones, as agents with high-predicted activity in human bladder cancer. Because even highly effective
monotherapy is unlikely to cure most patients with metastasis and NSC-645809 is undergoing clinical trials in other
tumor types, we sought to develop the basis for use of C1311 in rational combination with other agents in bladder
cancer. Here, we demonstrate in 40 human bladder cancer cells that the in vitro cytotoxicity profile for C1311 corre-
lateswith that of NSC-637993 and compares favorably to that of standard of care chemotherapeutics. Using genome-
wide patterns of synthetic lethality of C1311 with open reading frame knockouts in budding yeast, we determined
that combining C1311 with a taxane could provide mechanistically rational combinations. To determine the preclini-
cal relevance of these yeast findings, we evaluated C1311 singly and in doublet combinationwith paclitaxel in human
bladder cancer in the in vivo hollow fiber assay and observed efficacy. By applying COXEN to gene expression data
from 40 bladder cancer cell lines and 30 human tumors with associated clinical response data to platinum-based
chemotherapy, we provide evidence that signatures of C1311 sensitivity exist within nonresponders to this regimen.
Coupling COXEN and yeast chemigenomics provides rational combinations with C1311 and tumor genomic signa-
tures that can be used to select bladder cancer patients for clinical trials with this agent.
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Introduction
Bladder cancer is common and costly [1]. Nearly 30% of patients pres-
ent with muscle invasive bladder tumors at diagnosis, and approxi-
mately 50% of these patients develop distant recurrence and require
systemic chemotherapy [2]. With standard platinum combination
therapy (commonly cisplatin or carboplatin and gemcitabine, GC), a
median survival of only 13 months can be achieved in patients with
advanced disease, with modest response rates reported for second line
agents for treatment failures [3].
We have recently reported an informatics approach termed COXEN,
for coexpression extrapolation, that uses cell line transcriptional signa-
tures and associated in vitro sensitivity to therapeutic compounds to
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predict sensitivity of independent cell line panels and patient responses
to such agents [4]. The novel aspect of this approach is its ability to
select from sensitivity biomarker genes derived from cell lines a subset
that maintain concordant expression in a second cohort of cell lines or
human tumor samples. Importantly, this analysis is done a priori, with-
out knowledge of the pattern of sensitivity or clinical response is in the
second set. Originally reported as predictive of the outcomes of sepa-
rate clinical studies in 84 patients [5], recently this algorithm has been
used successfully to stratify clinical outcomes nearly 500 patients with
diverse tumor types [6].
One COXEN application we have reported is in drug discovery,
using publicly available data for 45,545 compounds from the US
NCI Developmental Therapeutics Program’s screen of 60 cell lines
from nine different tumor histologies (NCI-60) [7]. Because bladder
cancer cell lines were not part of the NCI-60, we used COXEN to pre-
dict which of the 45,000 drugs would be highly active in human blad-
der cancer. Top hits from this analysis included NSC-637993 and
NSC-645809 (C1311), two imidazoacridinone class compounds.
Evaluation of NSC-637993 on a panel of 40 bladder cancer cell lines
indicated that more than 60% exhibited 50% growth inhibition at the
micromolar level or better [5].
The imidazoacridinones are a promising new class of compounds
for human cancer [8] and are thought to function through several
mechanisms.Work with C1311 suggests that its mechanisms of action
may include DNA intercalation [9], as well as inhibition of topoisomer-
ase II [10] and the FLT3 tyrosine kinase [11]. Recent studies additionally
suggest that the mechanism of inhibition of topoisomerase IImay be due
to C1311 interfering with ATP binding to the enzyme, perhaps in a fash-
ion analogous to its inhibition of FLT3 [12]. Given our in vitro results
withNSC-637993 in bladder cancer cells and promising results obtained
for C1311 in early clinical trials in other tumor types [13,14], we decided
to perform a preclinical evaluation for these two related molecules in
bladder cancer with the intent to pave the way for future clinical trials
with these agents.
Because essentially no cures are observed in the setting of second-
line therapy for metastatic disease treated with single agents [3], we
applied yeast chemical genetics methods to define and then validate
in human bladder cancer, rational combination therapy with C1311.
In addition, given our success withCOXEN-based gene expression sig-
natures in predicting chemotherapeutic outcomes, we also provide
evidence that, among patients who fail first-line platinum chemother-
apy for metastatic bladder cancer, there exists a cohort that exhibits
transcriptional signatures suggestive of response to C1311.
Materials and Methods
Cell Culture, In Vitro, and In Vivo Drug Sensitivity
All human bladder cancer cells (BLA-40 panel), culture condi-
tions, and our protocol for assay of drug sensitivity have been re-
ported previously [5,15]. IC50 values (concentrations capable of
inducing 50% inhibition of cellular growth) were calculated for
the 40 cell lines using an improved Spline-fitting approach in the
statistics suite, R (www.R-project.org). In vivo sensitivity studies used
the hollow fiber assay (HFA), reported before [16], and in Supplemen-
tary Methods. The significance of growth inhibition in HFA results was
tested by single-sample t tests against the hypothesis that there was no
inhibition, in PRISM (GraphPad Software, La Jolla, CA), with two-
sided P values reported.
Competitive Yeast Growth Experiments
In Saccharomyces cerevisiae, mutant strains with knockouts of all non-
lethal open reading frames (ORFs; ∼4600) are available that are tagged
with two unique oligonucleotide “barcodes” that are flagged by universal
polymerase chain reaction primers for detection through microarrays,
as detailed before [17]. For competitive growth experiments, the col-
lection of homozygous diploid mutant cells (EUROSCARF; Institute
of Molecular Biosciences, Frankfurt, Germany) were grown on YPD
agar containing G418, pooled and frozen in 0.23-ml aliquots at OD =
21.5. For YPD growth, cells were diluted to 6.17 × 10 E7 cells/ml
and grown to saturation (five generations). Cultures were sequentially
diluted to 6.17 × 10 E7 cells/ml for consecutive growth experiments
(10, 15, and 20 generations). C1311 stocks were maintained at
100 μM in DMSO, and cells were treated with 0, 1, or 5 μl in YPD
plus 1% DMSO. Benomyl treatment was at 15 μg/ml in YPD plus
1% DMSO. Genomic DNA was recovered using MasterPure yeast
DNA purification kit (EPICENTRE Biotechnologies, Madison, WI)
and hybridized to Affymetrix Yeast TAG4.0 microarrays (Affymetrix
Inc, Santa Clara, CA) as per the manufacturer’s instructions.
Analysis of Yeast TAG Array and Synthetic Lethal Data
The Affymetrix Yeast TAG4.0 array data were analyzed using the
software developed by the Giaever laboratory, which normalizes, qual-
ity filters, and background adjusts data as detailed in the Supplemen-
tary Methods and previous publication [18]. The Yeast TAG4.0 drug
data as well as synthetic lethal data were binarized, assigning a 1 to syn-
thetic lethal query-target pairs and 0 to all other ORF pairs. Combin-
ing the drug and synthetic lethal data resulted in a binary matrix with
1521 rows of yeast query genes and 6 drug treatments (4 C1311 and
2 benomyl) and 2804 columns of yeast target genes. We note that the
original size of each drug binary vector was 6431 (i.e., the number of
yeast deletion strains interrogated on the array) and reduced to 2804
after being projected onto the set of available yeast target genes. These
data were clustered in two dimensions (i.e., cluster both rows and
columns) with a cosine distance metric to this 1521 × 2804 binary
matrix using the clustergram function in MATLAB Version 7.9.0
(MathWorks, Natick, MA). Lists of yeast strains with reduced fitness
for benomyl and C1311 were examined for statistically significant
enrichment of gene ontology terms by GO::TermFinder [19] using
default settings.
Drug Sensitivity Correlation Analyses
We calculated Spearman correlations between C1311 and NSC-
637993 compound data, paired distributions for C1311 and NSC-
637993 were compared using the Wilcoxon matched-pairs test, in
MATLAB and PRISM, respectively. For correlation analysis of the
∼4600 developmental therapeutics program drugs [20] to C1311 across
the NCI-60, we calculated Spearman correlation coefficients of cell
line IC50 values for C1311 to all other drugs, calculated Benjamini-
Hochberg–corrected P values, and used Kernel-Smoothing function
to plot the distribution of correlation coefficients, all in MATLAB.
Training and Testing COXEN-Based Classifier
Gene expression profiling of the BLA-40 bladder cancer panel
[GEO:GSE5845] [15] and that of the NCI-60 panel [GEO:
GSE5720] [21] and in vitro testing data for the compounds [22] were
used. For detailed methods on interplatform prediction of C1311 sen-
sitivity and biomarker selection, see Supplementary Methods.
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Results
Cytotoxicity of Imidazoacridinones on Human Bladder Cancer
Cells In Vitro and In Vivo
Having discovered that NSC-637993 exhibits activity in many
bladder cancer cell lines [5], we were interested whether the related
imidazoacridinone, C1311, might also have activity in bladder cancer.
We generated dose-response curves for C1311 in our 40 bladder cancer
cell lines (BLA-40) [15] across a concentration range of five logs,
estimated IC50 concentrations, and compared them to IC50 values
for NSC-637993 for the same panel. We observed robust activity of
C1311 in these cells, with IC50 values uncorrelated to the expression
of TOP2A (rs = −0.11,P = .52) and FLT3 (rs = −0.26, P = .11), putative
targets of C1311 (Figure 1A; for complete data, see Table W1 and
Figure W1).
Given the structural and functional similarity of C1311 to NSC-
637993, we wished to determine whether IC50 values for NSC-
637993 and C1311 were correlated. We found that the IC50 values
of the two drugs were significantly correlated (Figure 1B, rs = 0.44,
P = .006), whereas there was no significant difference between the
paired distributions of IC50 values for C1311 and NSC-637993
(P = .42) across these cells. This is consistent with data for the NCI-
60 panel of cells, for which a similar correlation was also observed (rs =
0.51, P < .01), as well as a trend toward superiority of C1311 over
NSC-637993 (P < .01; not shown). In addition, we observed that
C1311 compares favorably with cisplatin and gemcitabine, the
standard-of-care drugs for bladder cancer (Figure 1C ).
We next tested these compounds in vivo using HFA [16]. On the
basis of our in vitro characterization of sensitivity to C1311 and NSC-
637993 (Table W1) as well as evaluation of cell lines for compatibility
with the HFA, we selected one cell line exhibiting a low IC50 (T24T,
sensitive), two cell lines with intermediate IC50 values (FL3 and
UMUC1), and one cell line with a high IC50 (KK47, resistant) to
C1311, as indicated in Table 1 for HFA studies.Mice were treated four
times daily at 20 mg/kg by intraperitoneal injection, with animals
killed at 96 hours for quantitative measurement of cell growth. Com-
pared with untreated animals, we found that, in three of four cell lines
tested, there was a significant inhibition of growth (all P ≤ 0.02), the
exception being the resistant KK47 cell line (Table 1). Similar results
were shown testing NSC-637993 in this assay (Table W2A).
Chemigenomic Profiling in Yeast Suggests a Mode of Action
for C1311
Given the wide variety of potential targets reported for C1311 and
the imidazoacridinone class [8] as well as the need to better characterize
C1311’s mechanism for potential rational drug combinations [23], we
embarked on an unbiased, new strategy using budding yeast to begin
to characterize C1311’s mechanism. Recent advances in yeast genetics
enable high-throughput screening of yeast ORF deletion strains for
those that are sensitized to compounds or for synthetic lethal relation-
ships between two deletion mutants [24]. Formally, the analyses are
comparable; a compound may be effective because it inactivates a gene
product and is therefore similar to deletion of the ORF. Such analyses
have even yielded promising results for inference of conserved cellular
pathways perturbed by drugs by comparing the pattern of strains sen-
sitized to a drug to genome-wide genetic synthetic lethal relation-
ships [25].
We grew the pooled yeast deletion mutants in the presence of two
increasing concentrations of C1311 and profiled the strains remaining
after 10 and 20 generations of growth, compared with control-treated
pools, using Yeast TAG4.0 microarrays. For the lower concentration of
C1311, we found that 27 and 32 yeast strains showed significantly
reduced fitness when assayed after 10 and 20 generations. As expected,
at higher a concentration, we found more strains displaying reduced
Figure 1. C1311 and NSC exhibit similar, favorable in vitro activities,
comparable to standard-of-care agents. (A) IC50 values for C1311
were determined by Spline regression for the BLA-40 cell line panel,
plotted ranked ordered from left to right, then each corresponding
cell line’s expression of TOP2A and FLT3 expression (Affymetrix
probes 201291_s_at and 206674_at, both log10 values for visualization
in scale). (B) Scatter plot of NSC compound (ordinate) and C1311 (ab-
scissa) IC50 values across theBLA-40 panel, nonparametric Spearman
correlation, and P value. (C) Comparison of C1311 and standard-of-
caredrugsby IC50 across theBLA-40panel. IC50 valuesC1311, cisplatin,
and gemcitabine were rank ordered for the 40 cell lines for each drug
and plotted in ascending order on the log-scale y axis. The green,
pink, and blue arrows indicate the percentage of the BLA-40 cell lines
that exhibit IC50 values below the 1-μM range, demonstrating that
C1311 exhibits similar activity to agents currently in clinical use.
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fitness, 32 and 49, after 10 and 20 generations of growth, respectively.
We also found 12 (62.5-fold over mean expected by random chance)
and 15 (42.5-fold over mean expected by random chance) strains in
common when comparing the low- and high-concentration data at 10
and 20 generations, respectively, both P ≪ .0001. The highly nonran-
dom concordance in reduced fitness strains identified by separate growth
replicates treated at two different drug concentrations illustrates the sig-
nificant reproducibility of the results. The nonredundant union of the
strains that displayed reduced fitness at both concentrations and genera-
tions yielded 91 strains (Table W3A).
Combining our C1311 data with the 25,540 synthetic lethal inter-
actions identified in yeast (as of November 24, 2009 [17]) resulted in a
binary matrix with 1521 rows of yeast query genes. To cluster these
data in an interpretable way and allow comparison of the pattern of
strains sensitized to C1311 to genome-wide synthetic lethal interac-
tions, as has identified pathways targeted by drugs before [25], we used
two-dimensional hierarchical clustering, as shown in Figure 2, A to C .
The C1311 replicates (two concentrations after 10 or 20 generations of
competitive growth) cluster immediately next to each other into a re-
gion of the clustergram enriched with ORFs involved with membrane
lipid biogenesis (erg2 erg6 erg24 and erg28; Figure 2B). We interpreted
this as suggesting a function for C1311 in perturbing cellular lipid
biosynthesis or membrane function. Also consistent with this finding,
using gene ontology to evaluate the 91 C1311 reduced fitness strains
(Table W3A), we found a highly significant enrichment of gene ontol-
ogy terms related to several lipid biogenesis pathways (Table 2A).
Chemigenomic Profiling in Yeast Identifies Known
Taxane Targets
New anticancer agents are tried first in the setting of primary treat-
ment failure, meaning a potential future trial would use C1311 alone
or a C1311-based combination regime after failure of GC [26]. Pacli-
taxel, a taxane, has shown substantial activity both alone and in
combination therapies for bladder cancer [27] and is the leading
second-line agent in practice today. Hence, a doublet combination
of C1311 with paclitaxel would seem appealing.
Evaluation of paclitaxel in the chemigenomic assay would provide
two significant insights. First, it would validate our chemigenomic ap-
proach because the molecular target of taxanes is known, supporting
the premise that deletion strains sensitized to C1311 (Table W3A)
identify its true mode of action. Second, if comparison of such un-
biased evaluation of taxanes mode of action with that of C1311 reveals
little overlap, such information would support combination treatment
with these two drugs [23]. Here we use benomyl, an antitubulin drug
that inhibits β-tubulin–like paclitaxel because the latter does not bind
yeast β-tubulin because of the slight differences in the sequences of the
proteins between yeast and humans [28].
Using a sublethal concentration of benomyl to treat pooled yeast
deletion mutants and assaying by the same microarray platform after
10 or 20 generations of competitive growth, we found 32 and 16 sig-
nificantly reduced strains (a union resulting in 34 strains; TableW3B).
These data cluster immediately beside each other in a region of the
clustergram that is highly enriched in genes that function in the mitotic
spindle and immediately beside the tub3 tubulin deletion mutant
(Figure 2C ). These findings provide “proof-of-principle” because the
pattern of synthetic sensitivities caused by inhibiting microtubule
function with benomyl is most similar to inactivating tubulin with
through deletion mutation, confirming that our approach may define
modes of action of drugs. Also supporting this finding, when we used
GO::TermFinder, the 34 benomyl-sensitized strains showed signifi-
cant enrichment of terms relating to tubulin complex formation,
among others (Table 2B).
Nonoverlapping Pathways and Sensitivities for C1311
and the Taxane Benomyl
To examine whether the strains identified as synthetic lethal to
C1311 and benomyl (Table W3) significantly overlapped, we used
the χ 2 test, finding no significant overlap (two strains, P = .14, Yates
corrected). Given that the strains that showed reduced fitness to the
drugs were essentially mutually exclusive, these findings are consistent
with C1311 and benomyl having distinct modes of action in yeast.
However, to provide additional support for the strategy of combining
imidazoacridinones with taxanes, we availed ourselves to published
data encompassing ∼4400 drugs tested across the aforementioned
NCI-60 cell line panel [20]. Such data afford the opportunity to test
correlation of each drug’s pattern of IC50 values across the 60 cell lines
to that of C1311, allowing objective comparisons of patterns of each
drug to C1311 but also relative comparisons among a large number of
diverse bioactive compounds. Consistent with their targeting disparate
cellular pathways, we found that paclitaxel was nonsignificantly corre-
lated to C1311 at a level of rs = 0.25 (P = .11), essentially indistinguish-
able from the average correlation of rs = 0.24 (P = .27) across all drugs.
Interestingly, even the standard-of-care, GC doublet drugs, cisplatin,
and gemcitabine were more significantly correlated to C1311 than
paclitaxel (rs = 0.56, P < .0001, rs = 0.58, P < .0001, respectively).
Figure 2D shows these findings graphically, plotted against the ranked
distribution of correlations of the ∼4400 drugs. Taken together, these
findings from yeast and human cells suggested preclinical evaluation of
a paclitaxel C1311 doublet therapy, which we undertook below.
In Vivo Evaluation of Imidazoacridinone-Taxane
Combination Therapy in Human Bladder Cancer
For C1311 or NSC-637993 plus paclitaxel doublet HFA experi-
ments, we used our previously reported in vitro IC50 data for paclitaxel
in the BLA-40 panel [15] to select cell lines evincing several informa-
tive combinations of paclitaxel versus C1311 sensitivities as indicated
in Table 3. We used a cell line with low IC50 values to both the imi-
dazoacridinones and paclitaxel (UMUC6), two cell lines with interme-
diate IC50 values to both (T24 and 5637), and KK47 that had high
IC50 values to both drug classes. Animals were treated by intraperito-
neal injection four times with C1311 or NSC (20 mg/kg) plus pacli-
taxel (15 mg/kg) and sacrificed at 96 hours. Comparing untreated and
doubly treated animals, we found that combinations were effective
against all cell lines (all P < .01), including KK47, which was resistant
to imidazoacridinone monotherapy (Table 3), with similar findings for
Table 1. HFA Results for C1311.
Cell Line C1311 Status* Log10 IC50 SQ
† P‡ IP§ P‡ Overall Overall P‡
T24T Sensitive −6.62 65.5 <.0001 71.0 .0006 68.3 <.0001
FL3 Intermediate −5.45 78.6 .014 58.3 <.0001 68.4 .0002
UMUC1 Intermediate −5.35 97.7 .067 60.5 <.0001 79.1 .02
KK47 Resistant −4.84 80.1 <.0001 101.8 .57 90.9 .10
*Relative sensitivity to C1311 of indicated cell line. Of cell lines adaptable to the hollow fiber assay,
four cell types of varying in vitro sensitivities were selected for validation in vivo.
†Average percentage of control growth across four replicates at the subcutaneous implantation site.
‡Two-tailed P value for single-sample t test against the hypothesis that the inhibition was 0%.
§Average percentage of control growth across four replicates at the intraperitoneal implantation site.
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combinations with NSC-637993 and paclitaxel (Table W2B). These
findings suggest that despite the significant differences between in vitro
screening and quantitative evaluation of the pharmacologic capacity of
the drugs to reach subcutaneous and intraperitoneal compartments
in vivo, C1311 (and NSC) remain highly effective, whereas addition
of paclitaxel expands the spectrum of cell lines inhibited significantly
by treatment.
Development of a Predictive Biomarker Model
of C1311 Sensitivity
Taken together, the promising in vitro and in vivo results for C1311
suggest the possibility of testing it in a future clinical trial, a setting
where significant efficiencies may achieved by biomarker-guarded se-
lection of patients most likely to respond to therapy [29]. In particular,
if gene expression signatures suggestive of sensitivity to C1311 were
present in patients who did not respond to cisplatin-based therapy,
such data would further support its evaluation.We examined this ques-
tion using the COXEN algorithm, which develops, based on drug sen-
sitivity and gene expression profiling in cell lines, gene expression
model (GEM) predictors of drug response in patients [4].
To derive a gene expression signature of C1311 sensitivity, we began
by selecting candidate sensitivity biomarkers by rank-based correlation
(rs = 0.4) of C1311 IC50 values across the NCI-60 panel, finding that
219/22283 Affymetrix HG-U133A microarray probes meet this crite-
rion (false discovery rate = 0.1 by random permutation testing, for
probe information and correlation coefficients, see Table W4). Evalu-
ation of the potential functional associations of these 219 probe sets
using the Ingenuity Pathway Analysis program identified the glycero-
phospholipid metabolism pathway as the most significantly enriched,
supporting in cancer cells our observations associating C1311 with lipid
biogenesis in budding yeast. Linoleic and arachidonic acid metabolic
pathways were also high scoring pathways (Table 4).
Figure 2. Chemigenomic analysis of C1311 and paclitaxel between yeast and human cells. (A) Two-way hierarchical cluster of a 1521 ×
2804 binary matrix where a black pixel represents either a synthetic lethal interaction between two yeast ORFs or reduced fitness
between a drug and a yeast deletion mutant, or a white pixel represents all other two-ORF or drug-ORF pairs. We highlight the
C1311 (red) and benomyl (green) clusters. (B) We see that C1311 is in a relatively sparse area of the matrix, and the four treatments
with C1311 (two concentrations after 10 or 20 generations of competitive growth) cluster immediately next to each other and among
several deletion strains involved with membrane lipid biogenesis, implicating this pathway in the function of C1311. (C) Enlarged inset
view of the benomyl cluster from (A) showing benomyl treatments for 10 and 20 generations and neighboring deletion strains, enriched
for microtubule and spindle components, as would be expected for this microtubule poison. (D) IC50 patterns across 60 cell lines for
∼4400 drugs from the 60 cell lines of NCI-60 screen [20] were correlated to that of C1311 and the probability distribution function of the
coefficients was plotted. Paclitaxel, cisplatin, and gemcitabine exhibited the indicated correlation coefficients.
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We then applied a critical aspect of the COXEN algorithm to un-
cover which of the 219 probe sets were concordantly expressed across
three data sets (NCI-60, BLA-40, and a published bladder tumor data
set [30]) and then derive a GEM predicting C1311 sensitivity from
them. The human tumor data set was included so that the model could
be applied on human tumor data sets, as we have reported before [6].
We systematically examined subsets of the 219 C1311-associated
probes that maintained concordant expression between the three data
sets as described in SupplementaryMethods 1, for performance in pre-
dicting sensitivity of BLA-40 cells based on the similarity of their gene
expression to the NCI-60 cells used for training. The maximally
performing subset of five probes (Table W4) exhibited highly concor-
dant expression between all three of the aforementioned data sets and
was implemented in a weighted k nearest-neighbor (weighted kNN)
classifier in our final GEM [31]. This strategy assigned a prediction
for each BLA-40 test sample, based on the correlation of it its expres-
sion of the five probes, to sensitive and resistant groups of NCI-60
cells. The GEM exhibited significant ability to predict the sensitivity
of the BLA-40 from the NCI-60 (P = .01; Figure 3A). For full details
on the development of GEM, please see Supplementary Methods 1.
Evaluation of the C1311 GEM in Patients Undergoing
Platinum-Based Chemotherapy
To test whether the GEM-identified signatures of sensitivity among
patients showed resistance to cisplatin-based therapy, we tested it on
the microarray data for a cohort of 30 patients, published by Als et al.
[32], where the response to standard cisplatin-based chemotherapy was
known. We also used it to evaluate another reported microarray study
by Sanchez-Carbayo et al. [30] to examine the association of the
GEM’s predictions with other clinicopathologic characteristics. Both
studies profiled histologically verified, fresh-frozen primary tumor tis-
sues (biopsies and surgical resection specimens, respectively) on the
Affymetrix HG-U133A platform. Figure 3B demonstrates through
hierarchical clustering how the two cell lines and two human tumor data
sets are capable of being clustered together in an interpretable fashion
across the five COXEN-selected C1311 sensitivity GEM genes.
Table 2. Gene Ontology Term Enrichment among C1311- (A) and Benomyl- (B) Sensitized Yeast Strains.
GOID* GO_Term* Cluster Frequency Background Frequency P†
(A)
6629 Lipid metabolic process 19/90 genes, 21.1% 259/7166 background, 3.6% 1.17E−07
44255 Cellular lipid metabolic process 18/90 genes, 20.0% 254/7166 background, 3.5% 6.51E−07
8610 Lipid biosynthetic process 12/90 genes, 13.3% 140/7166 background, 2.0% 5.66E−05
9987 Cellular process 81/90 genes, 90.0% 4819/7166 background, 67.2% .00015
16126 Sterol biosynthetic process 6/90 genes, 6.7% 33/7166 background, 0.5% .00111
6694 Steroid biosynthetic process 6/90 genes, 6.7% 33/7166 background, 0.5% .00111
9058 Biosynthetic process 46/90 genes, 51.1% 2011/7166 background, 28.1% .00112
44249 Cellular biosynthetic process 45/90 genes, 50.0% 1994/7166 background, 27.8% .00239
16129 Phytosteroid biosynthetic process 5/90 genes, 5.6% 26/7166 background, 0.4% .0059
6696 Ergosterol biosynthetic process 5/90 genes, 5.6% 26/7166 background, 0.4% .0059
16125 Sterol metabolic process 6/90 genes, 6.7% 46/7166 background, 0.6% .0082
6631 Fatty acid metabolic process 6/90 genes, 6.7% 46/7166 background, 0.6% .0082
8202 Steroid metabolic process 6/90 genes, 6.7% 46/7166 background, 0.6% .0082
16128 Phytosteroid metabolic process 5/90 genes, 5.6% 28/7166 background, 0.4% .00864
8204 Ergosterol metabolic process 5/90 genes, 5.6% 28/7166 background, 0.4% .00864
(B)
43486 Histone exchange 5/33 genes, 15.2% 10/7166 genes, 0.1% 4.52E−08
7021 Tubulin complex assembly 4/33 genes, 12.1% 5/7166 genes, 0.1% 2.24E−07
43044 ATP-dependent chromatin remodeling 5/33 genes, 15.2% 29/7166 genes, 0.4% 2.00E−05
7023 Post-chaperonin tubulin folding pathway 3/33 genes, 9.1% 5/7166 genes, 0.1% .00011
34728 Nucleosome organization 5/33 genes, 15.2% 51/7166 genes, 0.7% .00037
43933 Macromolecular complex subunit organization 11/33 genes, 33.3% 470/7166 genes, 6.6% .00054
34621 Cellular macromolecular complex subunit organization 10/33 genes, 30.3% 392/7166 genes, 5.5% .00077
6338 Chromatin remodeling 5/33 genes, 15.2% 76/7166 genes, 1.1% .00268
6457 Protein folding 5/33 genes, 15.2% 86/7166 genes, 1.2% .00488
*GOID and GO Terms from the Gene Ontology Consortium, www.geneontology.org, identified by GO::TermFinder.
†Bonneferoni-corrected P value for enrichment of indicated term among yeast ORF knockout strains identified as exhibiting reduced fitness on growth with C1311 or benomyl (cluster frequency) to the
background frequency of such GO terms in the genome. All GOIDs presented were associated with an FDR approximating 0%.
Table 3. HFA Results for C1311 and Paclitaxel.
Tx Cell Line C1311 Status* Log10 IC50 Paclitaxel Status* Log10 IC50 SQ
† P‡ IP§ P‡ Overall Overall P‡
C1311 + Paclitaxel UMUC6 Sensitive −6.92 Sensitive −8.99 66.1 .0003 51.2 <.0001 58.7 <.0001
HTB9 Intermediate −5.64 Sensitive −8.93 40.5 .065 74.0 .0024 57.2 .0047
T24 Intermediate −5.66 Intermediate −7.36 76.9 .002 55.7 <.0001 66.3 <.0001
KK47 Resistant −4.84 Resistant >−7 70.9 <.0001 59.4 .0002 65.1 <.0001
*Relative responsiveness to C1311 or paclitaxel of indicated cell line. Of cell lines adaptable to the hollow fiber assay, four cell types of varying in vitro combinations of sensitivities to both drugs were
selected for validation in vivo. We have reported in vitro sensitivities to paclitaxel across the BLA-40 panel before [15].
†Average percentage of control growth across four replicates at the subcutaneous implantation site.
‡Two-tailed P value for single-sample t test against the hypothesis that the inhibition was 0%.
§Average percentage of control growth across four replicates at the intraperitoneal implantation site.
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Using the weighted kNN classifier to classify the human tumors, we
found in the chemotherapy study of Als et al. that distributions of our
C1311 prediction scores showed no differences among the study’s ob-
served chemotherapy response groups (P = .62; Figure 3C ), suggesting
that predictions were not reflective of general drug resistance and sup-
portive of the idea that candidates for C1311 treatment exist in non-
responders to standard-of-care drugs. In addition, in both studies of
Sanchez-Carbayo et al. and Als et al., we observed no difference in
C1311 sensitivity prediction scores based on patient age, sex, tumor
grade, or stage (data not shown). Furthermore, we did not observe sig-
nificant associations between our C1311 predictions and survival in
either data set (P = .46 and P = .54, respectively; Figure 3D). These
findings again suggest that the C1311 predictions are also not associ-
ated with general phenotypes, like aggressiveness of tumors, and are
independent of traditional pathologic factors and outcome, an impor-
tant requirement for molecular assays to have clinical utility [6].
Discussion
Efficient drug development relies on the identification of candidate
compounds, their preclinical validation in model systems, and transla-
tion in clinical trials. The availability of data from high-throughput
technologies such as drug screens on cell panels [7] or publicly available
gene expression profiling [33] provides building blocks that can be
synthesized with informatic tools such as COXEN to provide an
Table 4. Canonical Pathways Enriched in C1311-Correlated Microarray Probes.
Ingenuity Canonical Pathways* P† Ratio Molecules
Glycerophospholipid metabolism .004 3.11E−02 PPAP2B, PLA2R1, CHKA,
AGPAT1, PGS1, PCYT1A
N-glycan biosynthesis .028 3.23E−02 B4GALT4, ST6GAL1, MAN1C1
Riboflavin metabolism .028 3.64E−02 ACP5, ACP1
Arachidonic acid metabolism .045 1.76E−02 CYP2F1, CYP1A1, PLA2R1, PLOD1
Linoleic acid metabolism .048 2.42E−02 CYP2F1, CYP1A1, PLA2R1
Sphingolipid metabolism .059 2.68E−02 NAGA, PPAP2B, ASAH1
AMPK signaling .100 2.41E−02 MTOR, ACACB, STRADA, PPM1D
Glycerolipid metabolism .104 1.92E−02 NAGA, PPAP2B, AGPAT1
EIF2 signaling .107 3E−02 EIF2C2, EIF2AK2, GSK3B
*Ingenuity Pathway Analysis (IPA), Version 8, www.ingenuity.com.
†P values from IPA are Benjamini-Hochberg corrected.
Figure 3. Prediction of C1311 sensitivity between cell line panels and in human tumors. (A) COXEN analysis was used to develop a set of
probe sets associated with sensitivity to C1311 in the NCI-60 cell line panel and concordantly expressed between the NCI-60 panel, the
BLA-40 panel, and Sanchez-Carbayo et al. tumor gene expression data sets. Then, a nearest neighbor–based classification approach used
to classify the BLA-40 cell line panel based on the NCI-60 panel, and the ROC curve was plotted for the classes assigned (sensitive or
resistant) to test its ability to discriminate (area under the curve = 0.74, 95% CI = 0.59-0.90, P = .01). (B) Clustering of multiple data sets
by C1311 sensitivity genes. A two-dimensional hierarchical cluster of NCI-60, BLA-40, Sanchez-Carbayo et al., andAls et al. data sets across
28 three-way concordant probe sets. Individual NCI-60 (actual) and BLA-40 (predicted) cells are indicated by boxes, showing resistance in
yellow and sensitivity in green. Individual Sanchez-Carbayo et al. and Als et al. (both also predicted) tumor data sets are also indicated as for
the BLA-40 cells. The clustergram illustrates how the COXEN methodology may select concordant biomarkers between platforms such
that such gene expression patterns allow visualization or computational prediction of interpretable relationships between diverse biologic
systems. (C) C1311 prediction values were dot-scatter plotted for response classes from the Als et al. data set, including CR (complete
responder), PR (partial responder), NC (no change), and PD (progressive disease), finding no significant difference by nonparametric analy-
sis of variance. (D) Kaplan-Meier analysis of survival by C1311 prediction indicates no systematic association between C1311 prediction
class and survival in either study.
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integrated pipeline for drug development, an example of which we
report herein. We previously reported the discovery of NSC-637993
as a promising candidate compound for bladder cancer through the
COXEN algorithm; the first imidazoacridinone class drug to be so
evaluated for bladder cancer [5]. Among the top hits was a related
imidazoacridinone, C1311, with favorable activity, toxicity, and toler-
ability profiles [13,14,34]. Not surprisingly, we observed a correlation
of C1311 to NSC-637993 responsiveness, as well as a similar range
of IC50 values on bladder cell lines. Interestingly, our chemigenomic
screen using budding yeast suggested that C1311’s mechanism may
involve lipid biosynthesis pathways, a novel observation adding to
the large number of potential targets postulated for the drug in recent
reports [9,11,35–37]. This unexpected finding was nonetheless sup-
ported in mammalian cells by our observed enrichment of probes
for genes involved in glycerophospholipid metabolism among those
correlated to C1311 IC50 values across the NCI-60 cell line panel.
Our group is currently using these data to attempt to identify the target
and sensitizing agents for C1311.
The observation of essentially mutually exclusive patterns of syn-
thetic lethality between benomyl and C1311 provided a testable ther-
apeutic combination because of the similarity between benomyl and
the approved chemotherapeutic agent, paclitaxel [28]. Paclitaxel is
especially useful because it has complementary toxicities to those of
C1311 and has been used as monotherapy [15] in patients with ad-
vanced bladder cancer that have failed platinum agents [3]. Supporting
our observations of different classes of yeast knockouts conferring sen-
sitivity to the two drugs, correlation of sensitivity patterns of C1311
across the NCI-60 cell lines to 4463 drugs [20] found that C1311 and
paclitaxel were not correlated and even less correlated than C1311 to
cisplatin or gemcitabine. Also supportive of this concept is a previous
report of activity of C1311 in advanced breast cancer failures that
included taxane failures [37]. We performed an in vivo evaluation
for both C1311 and NSC-637993 using the National Institutes of
Health/National Cancer Institute–developed HFA and found that
both agents were effective alone in most bladder cancer cells. Impor-
tantly, combining these with paclitaxel in cells found to be resistant to
imidazoacridinone monotherapy, such as KK47, led to significant in-
hibition. Taken together, these data suggest that clinical evaluation of
C1311 with or without paclitaxel in the setting of cisplatin-based treat-
ment failures is warranted.
To optimize patient selection for bladder cancer clinical trials with
C1311, a biomarker for sensitivity to this drug is needed. In particular,
retrospective examination of such a biomarker or prediction model on
gene expression data from patients who have already been treated with
platinum regimens would provide an indication whether there is cross
resistance to C1311. Because COXEN-based classifiers have been
shown to be predictive of outcome in nearly 500 patients from nine
clinical trials [5,6], we used this technology to develop a GEM predict-
ing response to C1311. We found that COXEN predictions did not
differ significantly based on patient age, sex, tumor grade, or stage in
two different data sets of patients [30,32]. Making predictions on the
study of Als et al., which includes standard cisplatin-based therapy re-
sponse and survival outcome data, we found that predictions did not
differ significantly between patients evincing complete response, par-
tial response, no change, or progressive disease. An important limita-
tion of these findings is that, without data from an actual trial, it is not
possible to assign a cutoff value for prediction scores that definitively
identifies a responder or nonresponder to C1311. However, these
findings do suggest that our C1311 predictions were not simply an
index of tumor aggressivity or general drug resistance. Taken together,
they provide the rational framework for developing a future (biomarker-
selected or correlated) clinical trial of C1311 in the clinical setting of
cisplatin-based treatment failures.
In summary, we demonstrate that combining COXEN and yeast
chemigenomics allows formulation of rational drug combinations of
novel with established agents. Specifically, given the favorable charac-
teristics of C1311, clinical evaluation of this agent alone or in combi-
nation with paclitaxel, for patients with metastatic bladder cancer that
have failed first-line platinum therapy seems indicated.
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Supplementary Methods
Hollow Fiber Assay
National Institutes of Health and University of Virginia ACUC
guidelines were strictly observed. The National Cancer Institute
HFA, developed by Hollingshead et al. [1] was performed as described
to evaluate the in vivo activity of these two imidazoacridinone drugs
and in combination with other chemotherapeutics in two physiologic
compartments of the mouse, subcutaneous (SC) and intraperitoneal
(IP). We used an in vitro control incubation to verify cell viability,
sterility, and drug activity. Treated animals were compared to un-
treated controls with compounds administered daily on days 1 to 4
by IP injection. The compounds were administered once daily on
day 1 to 4 by IP injection. Individual mouse body weights were
recorded daily, and treatments would have been discontinued if an
individual mouse body weight decreased ≥3 g or if other signs of
toxicity/distress were evident, which did not occur. Imidazoacridi-
nones were given at 20 mg/kg daily × 4, whereas paclitaxel was added
at 15 mg/kg daily × 4. All mice were sacrificed on day 5, fibers were
removed, and viable cell mass was quantified by the “stable end point”
MTT dye conversion assay. Values presented are averages across four
treated mice.
Analysis of Yeast TAG Array and Synthetic Lethal Data
The Affymetrix Yeast TAG4.0 array data were analyzed using soft-
ware developed by the Giaever laboratory (http://chemogenomics.
stanford.edu/supplements/04tag/), which quantile normalizes up
and down tag intensities separately, applies quality filters, estimates
and subtracts background from the treatment and control intensities,
calculates log2 ratio of treatment over control enrichment, and identi-
fies yeast strains that display significantly reduced fitness in a group of
drug-treated replicates compared to control replicates. The method is
detailed in the software documentation and companion publication
[2]. The Yeast TAG4.0 drug data were converted to binary data as dis-
cussed in the Results section. Similarly, we converted the synthetic
lethal data to binary data by assigning a 1 to synthetic lethal query-
target pairs and 0 to all other ORF pairs. Combining the drug and syn-
thetic lethal data resulted in a binary matrix with 1521 rows of yeast
query genes and six drug treatments (four C1311 and two benomyl)
and 2804 columns of yeast target genes. We note that the original size
of each drug binary vector was 6431 (i.e., the number of yeast deletion
strains interrogated on the array) and reduced to 2804 after being
projected onto the set of available yeast target genes. We generated
Figure 2,A toC , by applying two-way hierarchical clustering (i.e., clus-
ter both rows and columns) with a cosine distancemetric to this 1521 ×
2804 binary matrix using the clustergram function in MATLAB Ver-
sion 7.9.0 (The Mathworks, Natick, MA). Lists of yeast strains with
reduced fitness for benomyl and C1311 were examined for statistically
significant enrichment of gene ontology terms by GO::TermFinder
[19] using default settings.
Development and Testing of a GEM Predictive
of C1311 Sensitivity
Data sets Used:
1. All data sets used are AffymetrixHG-U133A and publicly available.
2. The BLA-40 data set is available as GSE5845 at NCBI GEO
(www.ncbi.nlm.nih.gov/geo).
3. The NCI-60 cell line data set isGSE5720, also on NCBI GEO.
4. The Sanchez-Carbayo et al. data set is available as supplementary
data online with the referenced manuscript http://jco.ascopubs.
org/cgi/content/full/24/5/778 [3]
5. The Als et al. data set [4] is GSE5287, also on NCBI GEO.
6. In all cases, authors’ processed data were downloaded and used,
log-transformed (if not already) and z-scored for standardization
for inter–data set comparison.
Biomarker Discovery
The Spearman rank correlations of expression of each of the 22283
Affymetrix probes on the U133A platform across the NCI-60 cell line
panels to the C1311 IC50 values for these cells were first calculated in
Matlab (The Mathworks). To identify an appropriate cutoff point
for these correlation values, we conducted random permutation testing
to estimate the false discovery rate [5,6] at various cutoff values. We
carried out 100 random permutation tests and recorded how many
probes exhibited correlation values greater than the various cutoff
points tested. Specifically, we examined absolute correlation values
from 0.0 to 0.5 by 0.01 intervals, as shown:
By comparing the number of probes identified on average from
the random permutation tests versus the number identified in the ac-
tual data across the range of absolute correlation values mentioned,
we chose to accept a 10% false discovery rate rate, which represented
a threshold correlation coefficient (ρ) of 0.40. These methods iden-
tified 219 probes that exhibited a significant correlation to C1311.
Development and Testing of the GEM
To help further refine these 219 probes and uncover subsets main-
taining concordant expression between the two cell lines and human
tumor data sets, we next used an application of the cross-correlation
step of the COXEN algorithm, however, adapted to multiple data sets.
Three cross-correlation comparisons were made, namely 1) NCI-60 to
BLA-40, 2) NCI-60 to S-C et al., and 3) BLA-40 to S-C et al. To select
three-way concordant probes, we systematically examined a range of
cross-correlation coefficient cutoff values, specifically 0.00 to 0.50
by 0.01 intervals. At each cutoff value, we recorded the set of genes
exhibiting greater than threshold cross-correlation levels across all three
comparisons. For each set of concordant probes, we then conducted
the following procedures to assess their predictive performance in
the BLA-40:
1) Selection of C1311-sensitive and -resistant NCI-60 training
sets based on hierarchical clustering of cell lines across expression
of C1311 sensitivity probes. Using a semisupervised approach,
we discretized the continuous IC50 values in the NCI-60 data set into
groupings of “sensitive” and “resistant” cells to provide categorical
labels for the training data used in the development of a classifier. This
was done by clustering the NCI-60 cell lines based on the expression of
a given set of concordant C1311 sensitivity probes (described above) in
an agglomerative hierarchical tree (e.g., see A in the following graph).
Spearman correlation was used as the distance metric and the
unweighted pair group method with arithmetic mean as the linkage
function to construct the agglomerative hierarchical tree. Using the
cluster function of Matlab, the hierarchical tree was used to divide
the NCI-60 cells into two groups by drawing a horizontal cut through
the tree such that only two clusters remain. This cluster grouping
exhibited highly significant differences in NCI-60 IC50 values, as ex-
pected given our semisupervised approach (e.g., see B in the following
graph). Examination of the central tendencies of the IC50 values from
this grouping allowed us to appropriately label which cluster of the
grouping represented sensitive (low IC50) versus resistant (high IC50)
cell lines and use them for training data for the classifier.
2) Evaluation of significance of predictions on the BLA-40.
With these two groups of NCI-60 cells in hand, we next predicted
which class (sensitive or resistant) each of the BLA-40 cell lines was
most like. To do this, the NCI-60 and BLA-40 gene expression data
were first log transformed and then z-score standardized to enable
intercohort comparisons in correlation space. A weighted k nearest-
neighbor (weighted kNN) algorithm [7,8] was used as the classifier,
with the NCI-60 groupings from 1) serving as the training data and
predictions made for each cell line in the BLA-40 data set. A Spearman
correlation distance metric was used to weight the influence that train-
ing samples had on the prediction of test samples, and the prediction of
each test sample was based only on positively correlated training sam-
ples. The resulting predictions on the BLA-40 data set thus represent a
binary classification of “sensitive” or “resistant,” and we tested for dif-
ference in distributions of observed IC50 values for C1311 between
predicted sensitive and resistant classes by nonparametric t tests.
Following these two procedures systematically for each of the 0.00
to 0.50 cross-correlation cutoffs as outlined above, we identified a five-
gene model that best allowed us to differentiate resistant and sensitive
BLA-40 cell lines based on the expression patterns in the NCI-60 data
set (cross-correlation cutoff, or COXEN coefficient = 0.25). Impor-
tantly, the weighted kNN prediction algorithm used (Matlab Code
available on request) also provides a posterior probability estimate
for the classification call, a technique that has been reported before
[9]. The program then uses a threshold of greater than or less than
0.5 as the threshold for binary classification as sensitive or resistant.
We have termed this score the “C1311 sensitivity score,” which ranges
from 0 for sensitive to 1 for resistant, and it was the distributions of
these scores for individual patient tumors that were tested among
the different clinicopathologic characteristics in the data sets of
Sanchez-Carbayo et al. and Als et al.
Significance of Best Classifier Performance by Random
Permutation Testing
We next determined the exact statistical significance of these find-
ings through permutation testing. To prove that the results we have
generated thus far cannot be ascribed to “overtraining” or random
chance, we carefully carried out the identical procedures described
before but with 219 randomly selected probes. We then repeated this
random resampling test 500 times and recorded the P values for the
best-performingmodels, precisely as was done in 2)with the 219 genes
significantly associated to C1311 IC50 values in the NCI-60. This
allowed us to estimate the exact P value that results similar to or better
than those observed could be attributed to chance alone (P = .012), as
shown in the following graph:
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Figure W1. C1311 andNSC-637993 dose-response curves. Cellswere exposed to RPMI 1640/10%FBSmediumwith dilutedNSC-637993 or
C1311 at concentrations of 0 (control), 0.01, 0.1, 1, 10, and 100 μM; after 72 hours of culture, cell countswere assayed. Each concentration of
drug was tested on six replicate wells in more than 4 individual experiments. Data presented below for each of the cell lines show percent of
maximal cell growth (y axis) per drug, averaged across the four replicates, plotted against the log10 treatment dose. These drug-response




Table W1. Log10 IC50 Values for the BLA-40 Cell Line Panel.









































*The BLA-40 cell line panel has been reported before [15].
†Reported IC50 values for NSC-637993 [15] were recalculated using Spline regression and listed
here for comparison between the related imidazoacridinones.
‡Four of the BLA-40 cell lines were not tested for NSC-637993 in the prior report.
Table W2. HFA Results for NSC-637993 (A) and NSC and Paclitaxel (B).
(A)
Tx Cell Line NSC Log10 IC50 SC* P
† IP‡ P† Overall§ Overall P†
NSC Alone T24T −6.60 62.7 .005 71.6 .0006 61.3 <.0001
FL3 −6.40 66.0 .0002 56.6 <.0001 67.2 <.0001
UMUC1 −6.00 88.9 .2 54.9 <.0001 71.9 .0115
KK47 −6.20 118.0 .04 107.8 .0002 112.8 .0018
(B)
Tx Cell Line NSC Log10 IC50 Paclitaxel Log10 IC50
¶ SQ* P† IP‡ P† Overall Overall P†
NSC + Paclitaxel UMUC6 −6.28 −8.99 12.5 <.0001 27.0 <.0001 19.8 <.0001
HTB9 −5.94 −8.93 20.6 <.0001 8.1 <.0001 14.4 .0006
T24 −5.61 −7.36 62.8 <.0001 28.3 <.0001 45.6 <.0001
KK47 −6.20 >−7 94.3 .04 37.1 <.0001 65.7 .02
*Average percentage of control growth across four replicates at the subcutaneous implantation site.
†Two-tailed P value for single-sample t test against the hypothesis that the inhibition was 0%.
‡Average percentage of control growth across four replicates at the intraperitoneal implantation site.
§Average percentage of control growth across all replicates and sites.
¶We have reported in vitro sensitivities to paclitaxel across the BLA-40 panel before [16].
Table W3. Union of Yeast Strains with Reduced Fitness in C1311 (A) and Benomyl (B) Treatment.
Symbol Description
(A)
ACB1 Acyl-CoA-binding protein, transports newly synthesized acyl-CoA esters from fatty acid synthetase (Fas1p-Fas2p) to acyl-CoA-consuming processes
ACE2 Transcription factor that activates expression of early G1-specific genes, localizes to daughter cell nuclei after cytokinesis and delays G1 progression in daughters, localization is
regulated by phosphorylation; potential Cdc28p substrate
ADO1 Adenosine kinase, required for the utilization of S -adenosylmethionine (AdoMet); may be involved in recycling adenosine produced through the methyl cycle
AIM22 Putative lipoate-protein ligase, required along with Lip2 and Lip5 for lipoylation of Lat1p and Kgd2p; similar to E. coli LplA; null mutant displays reduced frequency of
mitochondrial genome loss
AKR1 Palmitoyl transferase involved in protein palmitoylation; acts as a negative regulator of pheromone response pathway; required for endocytosis of pheromone receptors; involved
in cell shape control; contains ankyrin repeats
ALG13 Catalytic component of UDP-GlcNAc transferase, required for the second step of dolichyl-linked oligosaccharide synthesis; anchored to the ER membrane through interaction
with Alg14p; similar to bacterial and human glycosyltransferases
ARC15 Subunit of the ARP2/3 complex, which is required for the motility and integrity of cortical actin patches
ARO1 Pentafunctional arom protein, catalyzes steps 2 through 6 in the biosynthesis of chorismate, which is a precursor to aromatic amino acids
ARO2 Bifunctional chorismate synthase and flavin reductase, catalyzes the conversion of 5-enolpyruvylshikimate 3-phosphate (EPSP) to form chorismate, which is a precursor to
aromatic amino acids
BEM2 Rho GTPase activating protein (RhoGAP) involved in the control of cytoskeleton organization and cellular morphogenesis; required for bud emergence
BEM4 Protein involved in establishment of cell polarity and bud emergence; interacts with the Rho1p small GTP–binding protein and with the Rho-type GTPase Cdc42p;
involved in maintenance of proper telomere length
BIM1 Microtubule-binding protein that together with Kar9p makes up the cortical microtubule capture site and delays the exit from mitosis when the spindle is oriented abnormally
BUD20 Protein involved in bud site selection; diploid mutants display a random budding pattern instead of the wild-type bipolar pattern
COY1 Golgi membrane protein with similarity to mammalian CASP; genetic interactions with GOS1 (encoding a Golgi snare protein) suggest a role in Golgi function
CPA1 Small subunit of carbamoyl phosphate synthetase, which catalyzes a step in the synthesis of citrulline, an arginine precursor; translationally regulated by an attenuator peptide
encoded by YOR302W within the CPA1 mRNA 5′-leader
CSR1 Phosphatidylinositol transfer protein with a potential role in regulating lipid and fatty acid metabolism under heme-depleted conditions; interacts specifically with thioredoxin
peroxidase; may have a role in oxidative stress resistance
CTF4 Chromatin-associated protein, required for sister chromatid cohesion; interacts with DNA polymerase α (Pol1p) and may link DNA synthesis to sister chromatid cohesion
CYB5 Cytochrome b5, involved in the sterol and lipid biosynthesis pathways; acts as an electron donor to support sterol C5-6 desaturation
DYN1 Cytoplasmic heavy chain dynein, microtubule motor protein, required for anaphase spindle elongation; involved in spindle assembly, chromosome movement, and spindle
orientation during cell division, targeted to microtubule tips by Pac1p
ERG2 C-8 sterol isomerase, catalyzes the isomerization of the delta-8 double bond to the delta-7 position at an intermediate step in ergosterol biosynthesis
ERG25 C-4 methyl sterol oxidase, catalyzes the first of three steps required to remove two C-4 methyl groups from an intermediate in ergosterol biosynthesis; mutants accumulate the
sterol intermediate 4,4-dimethylzymosterol
ERG28 Endoplasmic reticulum membrane protein, may facilitate protein-protein interactions between the Erg26p dehydrogenase and the Erg27p 3-ketoreductase and/or tether these
enzymes to the ER, also interacts with Erg6p
ERG3 C-5 sterol desaturase, catalyzes the introduction of a C-5(6) double bond into episterol, a precursor in ergosterol biosynthesis; mutants are viable, but cannot grow on
nonfermentable carbon sources
ERG6 Delta(24)-sterol C-methyltransferase, converts zymosterol to fecosterol in the ergosterol biosynthetic pathway by methylating position C-24; localized to both lipid particles
and mitochondrial outer membrane
FEN2 Plasma membrane H+-pantothenate symporter; confers sensitivity to the antifungal agent fenpropimorph
GCR2 Transcriptional activator of genes involved in glycolysis; interacts and functions with the DNA-binding protein Gcr1p
GET2 Subunit of the GET complex; involved in insertion of proteins into the ER membrane; required for the retrieval of HDEL proteins from the Golgi to the ER in an ERD2
dependent fashion and for meiotic nuclear division
GLO4 Mitochondrial glyoxalase II, catalyzes the hydrolysis of S -D-lactoylglutathione into glutathione and D-lactate
GTR2 Putative GTP binding protein that negatively regulates Ran/Tc4 GTPase cycle; activates transcription; subunit of EGO and GSE complexes; required for sorting of Gap1p;
localizes to cytoplasm and to chromatin; homolog of human RagC and RagD
ISC1 Mitochondrial membrane localized inositol phosphosphingolipid phospholipase C, hydrolyzes complex sphingolipids to produce ceramide; activated by phosphatidylserine,
cardiolipin, and phosphatidylglycerol; mediates Na+ and Li+ halotolerance
MGA2 ER membrane protein involved in regulation of OLE1 transcription, acts with homolog Spt23p; inactive ER form dimerizes and one subunit is then activated by
ubiquitin/proteasome–dependent processing followed by nuclear targeting
MGM1 Mitochondrial GTPase related to dynamin, present in a complex containing Ugo1p and Fzo1p; required for normal morphology of cristae and for stability of Tim11p;
homolog of human OPA1 involved in autosomal dominant optic atrophy
MNN11 Subunit of a Golgi mannosyltransferase complex that also contains Anp1p, Mnn9p, Mnn10p, and Hoc1p, and mediates elongation of the polysaccharide mannan backbone;
has homology to Mnn10p
MNN9 Subunit of Golgi mannosyltransferase complex also containing Anp1p, Mnn10p, Mnn11p, and Hoc1p that mediates elongation of the polysaccharide mannan backbone; forms
a separate complex with Van1p that is also involved in backbone elongation
MRPL16 Mitochondrial ribosomal protein of the large subunit
MSF1 Mitochondrial phenylalanyl-tRNA synthetase, active as a monomer, unlike the cytoplasmic subunit which is active as a dimer complexed to a β-subunit dimer; similar to the α
subunit of E. coli phenylalanyl-tRNA synthetase
NPT1 Nicotinate phosphoribosyltransferase, acts in the salvage pathway of NAD+ biosynthesis; required for silencing at rDNA and telomeres and has a role in silencing at mating-type
loci; localized to the nucleus
PDX3 Pyridoxine (pyridoxamine) phosphate oxidase, has homologs in E. coli and Myxococcus xanthus; transcription is under the general control of nitrogen metabolism
PER1 Protein of the endoplasmic reticulum, required for GPI-phospholipase A2 activity that remodels the GPI anchor as a prerequisite for association of GPI-anchored proteins with
lipid rafts; functionally complemented by human ortholog PERLD1
PFY1 Profilin, actin- and phosphatidylinositol 4,5-bisphosphate-binding protein, involved in cytoskeleton organization, required for normal timing of actin polymerization in
response to thermal stress; localizes to plasma membrane and cytosol
PGA1 Essential component of GPI-mannosyltransferase II, responsible for second mannose addition to GPI precursors as a partner of Gpi18p; required for maturation of Gas1p and
Pho8p; has synthetic genetic interactions with secretory pathway genes
PIB2 Protein binding phosphatidylinositol 3-phosphate, involved in telomere-proximal repression of gene expression; similar to Fab1 and Vps27
PPM1 Carboxyl methyltransferase, methylates the C-terminus of the protein phosphatase 2A catalytic subunit (Pph21p or Pph22p), which is important for complex formation with
regulatory subunits
PRO1 γ-Glutamyl kinase, catalyzes the first step in proline biosynthesis
RAD51 Strand exchange protein, forms a helical filament with DNA that searches for homology; involved in the recombinational repair of double-strand breaks in DNA during
vegetative growth and meiosis; homolog of Dmc1p and bacterial RecA protein
Table W3. (continued )
Symbol Description
RAD55 Protein that stimulates strand exchange by stabilizing the binding of Rad51p to single-stranded DNA; involved in the recombinational repair of double-strand breaks in DNA
during vegetative growth and meiosis; forms heterodimer with Rad57p
RAX2 N-glycosylated protein involved in the maintenance of bud site selection during bipolar budding; localization requires Rax1p; RAX2 mRNA stability is regulated by Mpt5p
RET2 Delta subunit of the coatomer complex (COPI), which coats Golgi-derived transport vesicles; involved in retrograde transport between Golgi and ER
RIM2 Mitochondrial pyrimidine nucleotide transporter; imports pyrimidine nucleoside triphosphates and exports pyrimidine nucleoside monophosphates; member of the
mitochondrial carrier family
RML2 Mitochondrial ribosomal protein of the large subunit, has similarity to E. coli L2 ribosomal protein; fat21 mutant allele causes inability to use oleate and may interfere with
activity of the Adr1p transcription factor
RPA135 RNA polymerase I subunit A135
RPB4 RNA polymerase II subunit B32; forms two subunit dissociable complex with Rpb7p; involved recruitment of 3′-end processing factors to transcribing RNA polymerase II
complex and in export of mRNA to cytoplasm under stress conditions
RPD3 Histone deacetylase; regulates transcription and silencing; plays a role in regulating Ty1 transposition
RPL13B Protein component of the large (60S) ribosomal subunit, nearly identical to Rpl13Ap; not essential for viability; has similarity to rat L13 ribosomal protein
RPL1A N-terminally acetylated protein component of the large (60S) ribosomal subunit, nearly identical to Rpl1Bp and has similarity to E. coli L1 and rat L10a ribosomal proteins;
rpl1a rpl1b double null mutation is lethal /// N-terminally acetylated protein component of the large (60S) ribosomal subunit, nearly identical to Rpl1Ap and has similarity to
E. coli L1 and rat L10a ribosomal proteins; rpl1a rpl1b double null mutation is lethal
RPL2B Protein component of the large (60S) ribosomal subunit, identical to Rpl2Ap and has similarity to E. coli L2 and rat L8 ribosomal proteins; expression is upregulated at low
temperatures
RPL35A Protein component of the large (60S) ribosomal subunit, identical to Rpl35Bp and has similarity to rat L35 ribosomal protein /// Protein component of the large (60S)
ribosomal subunit, identical to Rpl35Ap and has similarity to rat L35 ribosomal protein
RPL39 Protein component of the large (60S) ribosomal subunit, has similarity to rat L39 ribosomal protein; required for ribosome biogenesis; loss of both Rpl31p and Rpl39p confers
lethality; also exhibits genetic interactions with SIS1 and PAB1
RPS14A Ribosomal protein 59 of the small subunit, required for ribosome assembly and 20S pre-rRNA processing; mutations confer cryptopleurine resistance; nearly identical to
Rps14Bp and similar to E. coli S11 and rat S14 ribosomal proteins
RPS1B Ribosomal protein 10 (rp10) of the small (40S) subunit; nearly identical to Rps1Ap and has similarity to rat S3a ribosomal protein
RPS25A Protein component of the small (40S) ribosomal subunit; nearly identical to Rps25Bp and has similarity to rat S25 ribosomal protein
RSB1 Suppressor of sphingoid long chain base (LCB) sensitivity of an LCB-lyase mutation; putative integral membrane transporter or flippase that may transport LCBs from the
cytoplasmic side toward the extracytoplasmic side of the membrane
SAC1 Phosphatidylinositol phosphate (PtdInsP) phosphatase involved in hydrolysis of PtdIns[4]P; transmembrane protein localizes to ER and Golgi; involved in protein trafficking
and processing, secretion, and cell wall maintenance
SEC59 Dolichol kinase, catalyzes the terminal step in dolichyl monophosphate (Dol-P) biosynthesis; required for viability and for normal rates of lipid intermediate synthesis and
protein N-glycosylation
SGO1 Component of the spindle checkpoint, involved in sensing lack of tension on mitotic chromosomes; protects centromeric Rec8p at meiosis I; required for accurate chromosomal
segregation at meiosis II and for mitotic chromosome stability
SGS1 Nucleolar DNA helicase of the RecQ family involved in genome integrity maintenance; regulates chromosome synapsis and meiotic joint molecule/crossover formation; similar
to human BLM and WRN proteins implicated in Bloom and Werner syndromes
SMC3 Subunit of the multiprotein cohesin complex required for sister chromatid cohesion in mitotic cells; also required, with Rec8p, for cohesion and recombination during meiosis;
phylogenetically conserved SMC chromosomal ATPase family member
SNF1 AMP-activated serine/threonine protein kinase found in a complex containing Snf4p and members of the Sip1p/Sip2p/Gal83p family; required for transcription of
glucose-repressed genes, thermotolerance, sporulation, and peroxisome biogenesis
SOK2 Nuclear protein that plays a regulatory role in the cyclic AMP (cAMP)–dependent protein kinase (PKA) signal transduction pathway; negatively regulates pseudohyphal
differentiation; homologous to several transcription factors
SOV1 Mitochondrial protein of unknown function
SPO7 Putative regulatory subunit of Nem1p-Spo7p phosphatase holoenzyme, regulates nuclear growth by controlling phospholipid biosynthesis, required for normal nuclear
envelope morphology, premeiotic replication, and sporulation
SPT14 UDP-GlcNAc-binding and catalytic subunit of the enzyme that mediates the first step in glycosylphosphatidylinositol (GPI) biosynthesis, mutations cause defects in
transcription and in biogenesis of cell wall proteins
SSQ1 Mitochondrial hsp70-type molecular chaperone, required for assembly of iron/sulfur clusters into proteins at a step after cluster synthesis, and for maturation of Yfh1p, which
is a homolog of human frataxin implicated in Friedreich’s ataxia
SUR4 Elongase, involved in fatty acid and sphingolipid biosynthesis; synthesizes very long chain 20-26-carbon fatty acids from C18-CoA primers; involved in regulation of
sphingolipid biosynthesis
TBF1 Telobox-containing general regulatory factor; binds to TTAGGG repeats within subtelomeric anti–silencing regions (STARs) and possibly throughout the genome and mediates
their insulating capacity by blocking silent chromatin propagation
TIP20 Peripheral membrane protein required for fusion of COPI vesicles with the ER, prohibits back fusion of COPII vesicles with the ER, may act as a sensor for vesicles at the
ER membrane; interacts with Sec20p
TMA23 Nucleolar protein of unknown function implicated in ribosome biogenesis; TMA23 may be a fungal-specific gene as no homologs have been yet identified in higher eukaryotes
TRP3 Bifunctional enzyme exhibiting both indole-3-glycerol-phosphate synthase and anthranilate synthase activities, forms multifunctional hetero-oligomeric anthranilate
synthase:indole-3-glycerol phosphate synthase enzyme complex with Trp2p
VAC7 Integral vacuolar membrane protein involved in vacuole inheritance and morphology; activates Fab1p kinase activity under basal conditions and also after hyperosmotic shock
VPS65 Protein coding
VPS8 Membrane-associated protein that interacts with Vps21p to facilitate soluble vacuolar protein localization; component of the CORVET complex; required for localization and
trafficking of the CPY sorting receptor; contains RING finger motif
YIP1 Integral membrane protein required for the biogenesis of ER-derived COPII transport vesicles; interacts with Yif1p and Yos1p; localizes to the Golgi, the ER, and COPII vesicles
YML012C-A Hypothetical ORF
YMR290W-A Protein required for cell viability
YOR199W Hypothetical ORF
YPL080C Hypothetical ORF
YIL014C-A Putative protein of unknown function
YBR056W Putative cytoplasmic protein of unknown function
YBR221W-A Putative protein of unknown function; identified by expression profiling and mass spectrometry
YDL118W Nonessential protein of unconfirmed function; mutants are defective in telomere maintenance, and are synthetically sick or lethal with α-synuclein
YDL119C Putative mitochondrial transport protein; GFP fusion protein is induced in response to the DNA-damaging agent MMS; the authentic, nontagged protein is detected in
purified mitochondria
Table W3. (continued )
Symbol Description
(B)
ABD1 Methyltransferase, catalyzes the transfer of a methyl group from S -adenosylmethionine to the GpppN terminus of capped mRNA
AKR1 Palmitoyl transferase involved in protein palmitoylation; acts as a negative regulator of pheromone response pathway; required for endocytosis of pheromone receptors;
involved in cell shape control; contains ankyrin repeats
ARP6 Actin-related protein that binds nucleosomes; a component of the SWR1 complex, which exchanges histone variant H2AZ (Htz1p) for chromatin-bound histone H2A
BLM10 Proteasome activator subunit; found in association with core particles, with and without the 19S regulatory particle; required for resistance to bleomycin, may be involved in
protecting against oxidative damage; similar to mammalian PA200
BUB3 Kinetochore checkpoint WD40 repeat protein that localizes to kinetochores during prophase and metaphase, delays anaphase in the presence of unattached kinetochores; forms
complexes with Mad1p-Bub1p and with Cdc20p, binds Mad2p and Mad3p
CIN1 Tubulin folding factor D involved in β-tubulin (Tub2p) folding; isolated as mutant with increased chromosome loss and sensitivity to benomyl
CIN2 GTPase-activating protein (GAP) for Cin4p; tubulin folding factor C involved in β-tubulin (Tub2p) folding; mutants display increased chromosome loss and benomyl
sensitivity; deletion complemented by human GAP, retinitis pigmentosa 2
CIN4 GTP-binding protein involved in β-tubulin (Tub2p) folding; isolated as mutant with increased chromosome loss and sensitivity to benomyl; regulated by the GTPase-activating
protein, Cin2p, the human retinitis pigmentosa 2 (RP2) homolog
CMC1 Evolutionarily conserved copper-binding protein of the mitochondrial intermembrane space, may be involved in delivering copper from the matrix to the cytochrome c oxidase
complex; contains a twin CX9C motif
DAL82 Positive regulator of allophanate-inducible genes; binds a dodecanucleotide sequence upstream of all genes that are induced by allophanate; contains an UISALL
DNA-binding, a transcriptional activation, and a coiled-coil domain
ECM23 Nonessential protein of unconfirmed function; affects pre-rRNA processing, may act as a negative regulator of the transcription of genes involved in pseudohyphal growth;
homologous to Srd1p
ERG2 C-8 sterol isomerase, catalyzes the isomerization of the delta-8 double bond to the delta-7 position at an intermediate step in ergosterol biosynthesis
GIM3 Subunit of the heterohexameric cochaperone prefoldin complex which binds specifically to cytosolic chaperonin and transfers target proteins to it
GIM4 Subunit of the heterohexameric cochaperone prefoldin complex which binds specifically to cytosolic chaperonin and transfers target proteins to it
GND1 6-Phosphogluconate dehydrogenase (decarboxylating), catalyzes an NADPH regenerating reaction in the pentose phosphate pathway; required for growth on
D-glucono-delta-lactone and adaptation to oxidative stress
MGR3 Subunit of the mitochondrial (mt) i-AAA protease supercomplex, which degrades misfolded mitochondrial proteins; forms a subcomplex with Mgr1p that binds to substrates
to facilitate proteolysis; required for growth of cells lacking mtDNA
MTQ2 S -adenosylmethionine-dependent methyltransferase of the seven β-strand family; subunit of complex with Trm112p that methylates translation release factor Sup45p (eRF1)
in the ternary complex eRF1-eRF3-GTP; similar to E. coli PrmC
PAC10 Part of the heteromeric co-chaperone GimC/prefoldin complex, which promotes efficient protein folding
PAC2 Microtubule effector required for tubulin heterodimer formation, binds α-tubulin, required for normal microtubule function, null mutant exhibits cold-sensitive
microtubules and sensitivity to benomyl
PFD1 Subunit of heterohexameric prefoldin, which binds cytosolic chaperonin and transfers target proteins to it; involved in the biogenesis of actin and of α- and γ-tubulin
RVS161 Amphiphysin-like lipid raft protein; interacts with Rvs167p and regulates polarization of the actin cytoskeleton, endocytosis, cell polarity, cell fusion and viability following
starvation or osmotic stress
SET6 SET domain protein of unknown function; deletion heterozygote is sensitive to compounds that target ergosterol biosynthesis, may be involved in compound availability
STB5 Transcription factor, involved in regulating multidrug resistance and oxidative stress response; forms a heterodimer with Pdr1p; contains a Zn(II)2Cys6 zinc finger domain
that interacts with a pleiotropic drug resistance element in vitro
SWR1 Swi2/Snf2–related ATPase that is the structural component of the SWR1 complex, which exchanges histone variant H2AZ (Htz1p) for chromatin-bound histone H2A
TIF1 translation initiation factor eIF4E, 4F complex subunit (PMID 8955119)
TUB3 Alpha-tubulin; associates with β-tubulin (Tub2p) to form tubulin dimer, which polymerizes to form microtubules; expressed at lower level than Tub1p
UGO1 Protein of unknown function; outer membrane component of the mitochondrial fusion machinery; Ugo1p bind directly to Fzo1p and Mgm1p and thereby link these two
GTPases during mitochondrial fusion
VPS53 Component of the GARP (Golgi-associated retrograde protein) complex, Vps51p-Vps52p-Vps53p-Vps54p, which is required for the recycling of proteins from endosomes
to the late Golgi; required for vacuolar protein sorting
VPS71 Nucleosome-binding component of the SWR1 complex, which exchanges histone variant H2AZ (Htz1p) for chromatin-bound histone H2A; required for vacuolar protein sorting
VPS72 Htz1p-binding component of the SWR1 complex, which exchanges histone variant H2AZ (Htz1p) for chromatin-bound histone H2A; required for vacuolar protein sorting
YAF9 Subunit of both the NuA4 histone H4 acetyltransferase complex and the SWR1 complex, may function to antagonize silencing near telomeres; interacts directly with Swc4p,
has homology to human leukemogenic protein AF9, contains a YEATS domain
YKE2 Subunit of the heterohexameric Gim/prefoldin protein complex involved in the folding of α-tubulin, β-tubulin, and actin
YLR269C Hypothetical ORF
YML094C-A Hypothetical ORF
Table W4. C1311 IC50-Correlated Microarray Probes.
Probe Set* Rho† Symbol Gene Title Entrez Gene ID Cytoband
200661_at 0.4553 CTSA cathepsin A 5476 20q13.1
200677_at 0.4239 PTTG1IP pituitary tumor-transforming 1 interacting protein 754 21q22.3
200696_s_at 0.5067 GSN gelsolin (amyloidosis, Finnish type) 2934 9q33
200827_at 0.4218 PLOD1 procollagen-lysine 1, 2-oxoglutarate 5-dioxygenase 1 5351 1p36.22
201021_s_at 0.4644 DSTN destrin (actin depolymerizing factor) 11034 20p12.1
201022_s_at 0.434 DSTN destrin (actin depolymerizing factor) 11034 20p12.1
201032_at 0.4325 BLCAP bladder cancer associated protein 10904 20q11.2-q12
201038_s_at −0.4044 ANP32A acidic (leucine-rich) nuclear phosphoprotein 32 family, member A 8125 15q22.3-q23
201051_at −0.4105 ANP32A acidic (leucine-rich) nuclear phosphoprotein 32 family, member A 8125 15q22.3-q23
201148_s_at 0.4094 TIMP3 TIMP metallopeptidase inhibitor 3 7078 22q12.1-q13.2|22q12.3
201204_s_at 0.4182 RRBP1 ribosome binding protein 1 homolog 180 kDa (dog) 6238 20p12
201305_x_at −0.4189 ANP32B acidic (leucine-rich) nuclear phosphoprotein 32 family, member B 10541 9q22.32
201481_s_at 0.405 PYGB phosphorylase, glycogen; brain 5834 20p11.2-p11.1
201500_s_at 0.4222 PPP1R11 protein phosphatase 1, regulatory (inhibitor) subunit 11 6992 6p21.3
201525_at 0.475 APOD apolipoprotein D 347 3q26.2-qter
201618_x_at 0.4073 GPAA1 glycosylphosphatidylinositol anchor attachment protein 1 homolog (yeast) 8733 8q24.3
201629_s_at −0.4001 ACP1 acid phosphatase 1, soluble 52 2p25
201720_s_at −0.4154 LAPTM5 lysosomal protein transmembrane 5 7805 1p34
201775_s_at 0.4114 KIAA0494 KIAA0494 9813 1pter-p22.1
201987_at −0.4256 MED13 mediator complex subunit 13 9969 17q22-q23
202027_at 0.4175 TMEM184B transmembrane protein 184B 25829 22q12
202058_s_at 0.4398 KPNA1 karyopherin α 1 (importin α 5) 3836 3q21
202066_at 0.4728 PPFIA1 PTPRF interacting protein, α 1 8500 11q13.3
202219_at 0.4223 SLC6A8 solute carrier family 6, member 8 6535 Xq28
202421_at 0.4328 IGSF3 immunoglobulin superfamily, member 3 3321 1p13
202478_at 0.4103 TRIB2 tribbles homolog 2 (Drosophila) 28951 2p24.3
202479_s_at 0.5655 TRIB2 tribbles homolog 2 (Drosophila) 28951 2p24.3
202503_s_at −0.4017 KIAA0101 KIAA0101 9768 15q22.31
202609_at 0.4414 EPS8 epidermal growth factor receptor pathway substrate 8 2059 12q13
202629_at −0.457 APPBP2 amyloid β-precursor protein (cytoplasmic tail) binding protein 2 10513 17q21-q23
202818_s_at 0.4258 TCEB3 transcription elongation factor B (SIII), polypeptide 3 (110 kDa, elongin A) 6924 1p36.1
202821_s_at 0.4163 LPP LIM domain containing preferred translocation partner in lipoma 4026 3q28
202840_at −0.5074 TAF15 TAF15 RNA polymerase II, TATA box binding protein (TBP)–associated factor 8148 17q11.1-q11.2
202853_s_at 0.4478 RYK RYK receptor-like tyrosine kinase 6259 3q22
202894_at 0.4577 EPHB4 EPH receptor B4 2050 7q22
202943_s_at 0.4066 NAGA N-acetylgalactosaminidase, α- 4668 22q13-qter|22q11
202946_s_at 0.4029 BTBD3 BTB (POZ) domain containing 3 22903 20p12.2
203054_s_at 0.5192 TCTA T-cell leukemia translocation altered gene 6988 3p21
203137_at −0.4221 WTAP Wilms tumor 1 associated protein 9589 6q25-q27
203304_at 0.4496 BAMBI BMP and activin membrane–bound inhibitor homolog (Xenopus laevis) 25805 10p12.3-p11.2
203455_s_at 0.4052 SAT1 spermidine/spermine N1-acetyltransferase 1 6303 Xp22.1
203488_at 0.4243 LPHN1 latrophilin 1 22859 19p13.2
203657_s_at 0.4297 CTSF cathepsin F 8722 11q13
203832_at −0.4357 SNRPF small nuclear ribonucleoprotein polypeptide F 6636 12q23.1
204209_at 0.4157 PCYT1A phosphate cytidylyltransferase 1, choline, α 5130 3q29
204233_s_at 0.4287 CHKA choline kinase α 1119 11q13.2
204266_s_at 0.4633 CHKA choline kinase α 1119 11q13.2
204301_at −0.4881 KBTBD11 kelch repeat and BTB (POZ) domain containing 11 9920 8p23.3
204501_at 0.4265 NOV nephroblastoma overexpressed gene 4856 8q24.1
204528_s_at −0.4544 NAP1L1 nucleosome assembly protein 1-like 1 4673 12q21.2
204542_at 0.4563 ST6GALNAC2 ST6 -N-acetylgalactosaminide α-2,6-sialyltransferase 2 10610 17q25.1
204566_at −0.4076 PPM1D protein phosphatase 1D magnesium–dependent, delta isoform 8493 17q23.2
204626_s_at 0.4075 ITGB3 integrin, β3 (platelet glycoprotein IIIa, antigen CD61) 3690 17q21.32
204638_at 0.4635 ACP5 acid phosphatase 5, tartrate resistant 54 19p13.3-p13.2
204653_at 0.4107 TFAP2A transcription factor AP-2 α 7020 6p24
204654_s_at 0.4418 TFAP2A transcription factor AP-2 α 7020 6p24
204783_at 0.4152 MLF1 myeloid leukemia factor 1 4291 3q25.1
204789_at −0.5508 FMNL1 formin-like 1 752 17q21
204803_s_at −0.4276 RRAD Ras-related associated with diabetes 6236 16q22
205209_at −0.4004 ACVR1B activin A receptor, type IB 91 12q13
205334_at 0.4318 S100A1 S100 calcium binding protein A1 6271 1q21
205376_at 0.4913 INPP4B inositol polyphosphate-4-phosphatase, type II, 105 kDa 8821 4q31.21
205441_at 0.4227 OCEL1 occludin/ELL domain containing 1 79629 19p13.11
205749_at 0.4594 CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 1543 15q24.1
206066_s_at −0.4726 RAD51C RAD51 homolog C (S. cerevisiae) 5889 17q22-q23
206077_at 0.4308 KEL Kell blood group, metalloendopeptidase 3792 7q33
206305_s_at −0.4283 C8A complement component 8, α polypeptide 731 1p32
206523_at 0.4377 CYTH3 cytohesin 3 9265 7p22.1
206775_at 0.4011 CUBN cubilin (intrinsic factor-cobalamin receptor) 8029 10p12.31
206994_at 0.4623 CST4 cystatin S 1472 20p11.21
207039_at 0.4992 CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) 1029 9p21
207098_s_at 0.419 MFN1 mitofusin 1 55669 3q26.33
207714_s_at 0.4095 SERPINH1 serpin peptidase inhibitor, clade H, member 1 871 11q13.5
207833_s_at 0.4588 HLCS holocarboxylase synthetase 3141 21q22.1|21q22.13
Table W4. (continued )
Probe Set* Rho† Symbol Gene Title Entrez Gene ID Cytoband
207913_at 0.426 CYP2F1 cytochrome P450, family 2, subfamily F, polypeptide 1 1572 19q13.2
207938_at 0.4719 PI15 peptidase inhibitor 15 51050 8q21.11
207992_s_at −0.407 AMPD3 adenosine monophosphate deaminase (isoform E) 272 11p15
208291_s_at −0.4216 TH tyrosine hydroxylase 7054 11p15.5
208356_x_at −0.4035 CSH1 chorionic somatomammotropin hormone 1 (placental lactogen) 1442 17q24.2
208754_s_at −0.455 NAP1L1 nucleosome assembly protein 1–like 1 4673 12q21.2
208776_at −0.4355 PSMD11 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 5717 17q11.2
208949_s_at 0.5056 LGALS3 lectin, galactoside-binding, soluble, 3 3958 14q21-q22
208978_at 0.4147 CRIP2 cysteine-rich protein 2 1397 14q32.3
209054_s_at −0.4028 WHSC1 Wolf-Hirschhorn syndrome candidate 1 7468 4p16.3
209280_at −0.4334 MRC2 mannose receptor, C type 2 9902 17q23.2
209361_s_at 0.4418 PCBP4 poly(rC) binding protein 4 57060 3p21
209399_at 0.4037 HLCS holocarboxylase synthetase 3141 21q22.1|21q22.13
209484_s_at −0.4026 NSL1 NSL1, MIND kinetochore complex component, homolog (S. cerevisiae) 25936 1q41
209485_s_at 0.4055 OSBPL1A oxysterol binding protein-like 1A 114876 18q11.1
209598_at −0.4092 PNMA2 paraneoplastic antigen MA2 10687 8p21.2
209736_at 0.4124 SOX13 SRY (sex determining region Y)-box 13 9580 1q32
209744_x_at 0.4511 ITCH itchy E3 ubiquitin protein ligase homolog (mouse) 83737 20q11.22-q11.23
209849_s_at −0.4522 RAD51C RAD51 homolog C (S. cerevisiae) 5889 17q22-q23
209945_s_at 0.4391 GSK3B glycogen synthase kinase 3β 2932 3q13.3
210083_at 0.4181 SEMA7A semaphorin 7A, GPI membrane anchor 8482 15q22.3-q23
210194_at −0.5138 PLA2R1 phospholipase A2 receptor 1, 180 kDa 22925 2q23-q24
210235_s_at 0.4315 PPFIA1 PTPRF interacting protein, α 1 8500 11q13.3
210285_x_at −0.4267 WTAP Wilms tumor 1 associated protein 9589 6q25-q27
210740_s_at 0.411 ITPK1 inositol 1,3,4-triphosphate 5/6 kinase 3705 14q31
210854_x_at 0.4757 SLC6A8 solute carrier family 6, member 8 6535 Xq28
210980_s_at 0.4375 ASAH1 N-acylsphingosine amidohydrolase 1 427 8p22-p21.3
211381_x_at 0.403 SPAG11B sperm associated antigen 11B 10407 8p23-p22
211870_s_at 0.4171 PCDHA3 protocadherin α 3 56145 5q31
211883_x_at* 0.4335 CEACAM1 carcinoembryonic antigen–related cell adhesion molecule 1 634 19q13.2
211988_at −0.4108 SMARCE1 SWI/SNF related, matrix associated, subfamily e, member 1 6605 17q21.2
212007_at −0.4351 UBXN4 UBX domain protein 4 23190 2q21.3
212056_at −0.4018 KIAA0182 KIAA0182 23199 16q24.1
212086_x_at 0.4143 LMNA lamin A/C 4000 1q21.2-q21.3
212089_at 0.4162 LMNA lamin A/C 4000 1q21.2-q21.3
212226_s_at 0.4283 PPAP2B phosphatidic acid phosphatase type 2B 8613 1pter-p22.1
212230_at 0.4355 PPAP2B phosphatidic acid phosphatase type 2B 8613 1pter-p22.1
212252_at −0.4583 CAMKK2 calcium/calmodulin–dependent protein kinase kinase 2, β 10645 12q24.2
212338_at 0.41 MYO1D myosin ID 4642 17q11-q12
212375_at −0.4327 EP400 E1A binding protein p400 57634 12q24.33
212631_at 0.4084 STX7 syntaxin 7 8417 6q23.1
212747_at 0.4647 ANKS1A ankyrin repeat and sterile α motif domain containing 1A 23294 6p21.31
212807_s_at 0.5102 SORT1 sortilin 1 6272 1p21.3-p13.1|1p21.3-p13.1
212876_at 0.4171 B4GALT4 UDP-Gal:βGlcNAc β 1,4- galactosyltransferase, polypeptide 4 8702 3q13.3
212957_s_at 0.4444 LOC92249 hypothetical LOC92249 92249 Xq11.1
213236_at 0.4565 SASH1 SAM and SH3 domain containing 1 23328 6q24.3
213242_x_at 0.4868 KIAA0284 KIAA0284 283638 14q32.33
213293_s_at −0.4534 TRIM22 tripartite motif–containing 22 10346 11p15
213294_at −0.4017 — — — —
213310_at 0.4496 EIF2C2 Eukaryotic translation initiation factor 2C, 2 27161 8q24
213343_s_at 0.604 GDPD5 glycerophosphodiester phosphodiesterase domain containing 5 81544 11q13.4-q13.5
213472_at −0.4171 HNRNPH1 heterogeneous nuclear ribonucleoprotein H1 (H) 3187 5q35.3
213575_at −0.4166 TRA2A transformer 2 α homolog (Drosophila) 29896 7p15.3
213649_at −0.4247 SFRS7 splicing factor, arginine/serine–rich 7, 35 kDa 6432 2p22.1
213672_at −0.4654 MARS methionyl-tRNA synthetase 4141 12q13.2
213702_x_at 0.4707 ASAH1 N-acylsphingosine amidohydrolase 1 427 8p22-p21.3
213843_x_at 0.4967 SLC6A8 solute carrier family 6, member 8 6535 Xq28
213864_s_at −0.4207 NAP1L1 nucleosome assembly protein 1–like 1 4673 12q21.2
213902_at 0.4116 ASAH1 N-acylsphingosine amidohydrolase 1 427 8p22-p21.3
213921_at 0.4172 SST somatostatin 6750 3q28
213954_at −0.4715 FAM169A family with sequence similarity 169, member A 26049 5q13.3
214152_at 0.4033 CCPG1 cell cycle progression 1 9236 15q21.1
214172_x_at 0.455 RYK RYK receptor–like tyrosine kinase 6259 3q22
214180_at 0.4349 MAN1C1 mannosidase, α, class 1C, member 1 57134 1p35
214213_x_at 0.428 LMNA Lamin A/C 4000 1q21.2-q21.3
214280_x_at −0.4075 HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 3178 12q13.1
214584_x_at 0.444 ACACB acetyl-Coenzyme A carboxylase β 32 12q24.11
214635_at 0.4365 CLDN9 claudin 9 9080 16p13.3
214812_s_at −0.5214 MOBKL1B MOB1, Mps One Binder kinase activator–like 1B (yeast) 55233 2p13.1
214971_s_at 0.4022 ST6GAL1 ST6 β-galactosamide α-2,6-sialyltranferase 1 6480 3q27-q28
215017_s_at 0.4167 FNBP1L formin binding protein 1-like 54874 1p22.1
215096_s_at −0.4088 ESD esterase D/formylglutathione hydrolase 2098 13q14.1-q14.2
215381_at 0.4365 FRAP1 FK506 binding protein 12-rapamycin associated protein 1 2475 1p36.2
215495_s_at 0.4115 SAMD4A sterile α motif domain containing 4A 23034 14q22.2
Table W4. (continued )
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215535_s_at 0.4043 AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1 10554 6p21.3
215611_at −0.4135 TCF12 transcription factor 12 6938 15q21
215693_x_at 0.4599 DDX27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 55661 20q13.13
215731_s_at* −0.4896 MPHOSPH9 M-phase phosphoprotein 9 10198 12q24.31
215749_s_at 0.4258 GORASP1 golgi reassembly stacking protein 1, 65 kDa 64689 3p22-p21.33
215812_s_at 0.5162 LOC653562 similar to solute carrier family 6 member 8 — 16p11.2 /// Xq28
216032_s_at 0.4316 ERGIC3 ERGIC and golgi 3 51614 20pter-q12
216060_s_at 0.4403 DAAM1 dishevelled associated activator of morphogenesis 1 23002 14q23.1
216086_at 0.4003 SV2C synaptic vesicle glycoprotein 2C 22987 5q13.3
216560_x_at 0.4343 IGL@ immunoglobulin lambda locus 3535 22q11.1-q11.2
216629_at 0.4066 SRRM2 Serine/arginine repetitive matrix 2 23524 16p13.3
216751_at −0.4111 — — — —
216835_s_at −0.4124 DOK1 docking protein 1, 62 kDa (downstream of tyrosine kinase 1) 1796 2p13
216874_at 0.489 DKFZp686O1327 Hypothetical gene supported by BC043549; BX648102 401014 2q22.3
216976_s_at 0.4007 RYK RYK receptor–like tyrosine kinase 6259 3q22
217036_at 0.4367 LOC100293679 hypothetical protein LOC100293679 100293679 —
217094_s_at 0.4157 ITCH itchy E3 ubiquitin protein ligase homolog (mouse) 83737 20q11.22–q11.23
217573_at 0.4175 GRIN2C glutamate receptor, ionotropic, N–methyl D–aspartate 2C 2905 17q25
217606_at 0.4886 — — — —
217613_at −0.4542 TMEM144 transmembrane protein 144 55314 4q32.1
217730_at* 0.4432 TMBIM1 transmembrane BAX inhibitor motif containing 1 64114 2p24.3–p24.1
217749_at 0.4832 COPG coatomer protein complex, subunit γ 22820 3q21.3
217925_s_at 0.4097 C6orf106 chromosome 6 open reading frame 106 64771 6p21.31
218099_at 0.4599 TEX2 testis expressed 2 55852 17q23.3
218299_at 0.4424 C11orf24 chromosome 11 open reading frame 24 53838 11q13
218509_at 0.5167 LPPR2 lipid phosphate phosphatase–related protein type 2 64748 19p13.2
218670_at −0.4554 PUS1 pseudouridylate synthase 1 80324 12q24.33
218779_x_at 0.4243 EPS8L1 EPS8-like 1 54869 19q13.42
218936_s_at −0.4272 CCDC59 coiled-coil domain containing 59 29080 12q21.31
218963_s_at 0.4383 KRT23 keratin 23 (histone deacetylase-inducible) 25984 17q21.2
218970_s_at −0.4909 CUTC cutC copper transporter homolog (E. coli) 51076 10q24.2
219011_at 0.4364 PLEKHA4 pleckstrin homology domain containing, family A member 4 57664 19q13.33
219046_s_at 0.4165 PKNOX2 PBX/knotted 1 homeobox 2 63876 —
219108_x_at 0.4345 DDX27 /// SS18 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 — 18q11.2 /// 20q13.13
219112_at −0.4589 RAPGEF6 Rap guanine nucleotide exchange factor (GEF) 6 51735 5q31.1
219143_s_at 0.4134 RPP25 ribonuclease P/MRP 25 kDa subunit 54913 15q24.2
219278_at 0.4464 MAP3K6 mitogen-activated protein kinase kinase kinase 6 9064 1p36.11
219394_at −0.4245 PGS1 phosphatidylglycerophosphate synthase 1 9489 17q25.3
219428_s_at 0.4054 PXMP4 peroxisomal membrane protein 4, 24 kDa 11264 20q11.22
219450_at 0.4348 C4orf19 chromosome 4 open reading frame 19 55286 4p14
219569_s_at −0.4059 TMEM22 transmembrane protein 22 80723 3q22.3
219710_at 0.4466 SH3TC2 SH3 domain and tetratricopeptide repeats 2 79628 5q32
219873_at 0.4197 COLEC11 collectin subfamily member 11 78989 2p25.3
220038_at 0.4149 C8orf44 /// SGK3 chromosome 8 open reading frame 44 — 8q12.3-q13.1 /// 8q13.1
220499_at 0.443 FNDC8 fibronectin type III domain containing 8 54752 17q12
220559_at 0.4341 EN1 engrailed homeobox 1 2019 2q13-q21
220948_s_at 0.447 ATP1A1 ATPase, Na+/K+ transporting, α 1 polypeptide 476 1p21
220999_s_at −0.4167 CYFIP2 cytoplasmic FMR1 interacting protein 2 26999 5q33.3
221017_s_at 0.409 LRRC3 leucine rich repeat containing 3 81543 21q22.3
221215_s_at 0.4981 RIPK4 receptor-interacting serine-threonine kinase 4 54101 21q22.3
221410_x_at 0.4631 PCDHB3 protocadherin β3 56132 5q31
221489_s_at 0.4378 SPRY4 sprouty homolog 4 (Drosophila) 81848 5q31.3
221616_s_at −0.4113 TAF9B TAF9B RNA polymerase II 51616 Xq13.1-q21.1
221681_s_at −0.4101 DSPP dentin sialophosphoprotein 1834 4q21.3
221683_s_at −0.4697 CEP290 centrosomal protein 290 kDa 80184 12q21.32
221738_at 0.4105 KIAA1219 KIAA1219 57148 20q11.23
221816_s_at −0.4902 PHF11 PHD finger protein 11 51131 13q14.2
221819_at −0.4578 RAB35 RAB35, member RAS oncogene family 11021 12q24.31
221821_s_at* −0.4137 C12orf41 chromosome 12 open reading frame 41 54934 12q13.11
221900_at −0.4483 COL8A2 collagen, type VIII, α 2 1296 1p34.2
221919_at −0.4026 HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 3178 12q13.1
221965_at* −0.5905 MPHOSPH9 M-phase phosphoprotein 9 10198 12q24.31
221986_s_at 0.4164 KLHL24 kelch-like 24 (Drosophila) 54800 3q27.1
222347_at 0.4183 LOC644450 hypothetical protein LOC644450 644450 1q12
32502_at 0.4446 GDPD5 glycerophosphodiester phosphodiesterase domain containing 5 81544 11q13.4-q13.5
36888_at −0.4388 HAUS5 HAUS augmin–like complex, subunit 5 23354 19q13.12
38918_at 0.4097 SOX13 SRY (sex determining region Y)-box 13 9580 1q32
41644_at 0.4485 SASH1 SAM and SH3 domain containing 1 23328 6q24.3
52164_at 0.4047 C11orf24 chromosome 11 open reading frame 24 53838 11q13
52169_at −0.4345 STRADA STE20-related kinase adaptor α 92335 17q23.3
64899_at 0.4262 LPPR2 lipid phosphate phosphatase–related protein type 2 64748 19p13.2
*Probe set designation from the Affymetrix HG-U133A platform. The five probes exhibiting concordant expression across all three data sets are specifically asterisked.
†Correlation coefficient (ρ) for Spearman rank–based correlation of indicated probe expression in the NCI-60 cell line data set, GSE5720, to the C1311 IC50 values for each of the sixty cell lines. A cutoff
of 0.4 was used for biomarker discovery.
